Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2025)

Xeris Biopharma Holdings' Share-based Compensation history spans 6 years, with the latest figure at $5.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 46.65% year-over-year to $5.3 million, compared with a TTM value of $22.4 million through Dec 2025, up 21.8%, and an annual FY2025 reading of $22.4 million, up 21.8% over the prior year.
  • Share-based Compensation for Q4 2025 was $5.3 million at Xeris Biopharma Holdings, down from $7.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $7.6 million in Q3 2025, with the low at $2.5 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $3.7 million, with a median of $3.2 million recorded in 2022.
  • Year-over-year, Share-based Compensation dropped 22.33% in 2023 and then skyrocketed 175.46% in 2024.
  • Tracing XERS's Share-based Compensation over 5 years: stood at $2.7 million in 2021, then grew by 0.84% to $2.8 million in 2022, then increased by 0.04% to $2.8 million in 2023, then increased by 29.92% to $3.6 million in 2024, then surged by 46.65% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Share-based Compensation are $5.3 million (Q4 2025), $7.6 million (Q3 2025), and $5.0 million (Q2 2025).